



(51) International Patent Classification:

C07K 14/81 (2006.01) C07K 14/755 (2006.01)
C07K 14/005 (2006.01) A61K 39/215 (2006.01)
C07K 14/74 (2006.01) A61P 31/14 (2006.01)
C07K 14/705 (2006.01) A61K 39/00 (2006.01)

(21) International Application Number:

PCT/US2024/037523

(22) International Filing Date:

11 July 2024 (11.07.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/526,410 12 July 2023 (12.07.2023) US

(71) Applicants: **THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.** [US/US]; 6720-A Rockledge Drive, Suite 100, Bethesda, Maryland 20817 (US). **LEIDOS BIOMEDICAL RESEARCH INC.** [US/US]; 1050 Boyles Street, P.O. Box B, Frederick, Maryland 21702-1201 (US).

(72) Inventors: **MITRE, Edward, Elias, Saul**; c/o The Henry M. Jackson Foundation for the advancement of Military


Medicine, Inc., 6720-A Rockledge Drive, Suite 100, Bethesda, Maryland 20817 (US). **GRAYDON, Elizabeth, Kathleen**; c/o The Henry M. Jackson Foundation for the advancement of Military Medicine, Inc., 6720-A Rockledge Drive, Suite 100, Bethesda, Maryland 20817 (US). **ANDERSON, Stephen, Kent**; c/o Leidos Biomedical Research Inc., 1050 Boyles Street, P.O. Box B, Frederick, Maryland 21702-1201 (US).

(74) Agent: **BRINCKERHOFF, Courtenay, C.** et al.; Foley & Lardner LLP, 3000 K Street NW, Suite 600, Washington, District of Columbia 20007-5109 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: COMPOSITIONS AND METHODS FOR THE INHIBITION OF NATURAL KILLER CELLS

FIG. 13



(57) Abstract: The present disclosure relates to novel polynucleotide sequences, constructs, and cell hosts for expressing the same, and compositions comprising the same. The disclosure further relates to methods for using the novel polynucleotide sequences, constructs, cell hosts, and compositions. In some embodiments, a first polynucleotide encodes a polypeptide capable of having natural killer (NK) cell inhibiting activity; and a second polynucleotide encodes a polypeptide capable of inducing an immune response or encoding a naturally endogenously produced protein.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*